Key points are not available for this paper at this time.
The rising interest in developing radiopharmaceuticals as cancer treatments is sparking increased investment in manufacturing these therapies. This month, Orano Med inaugurated a laboratory in Brownsburg, Indiana, near Indianapolis, where it will produce α radiotherapies for oncology. The company put 20 million into the 2, 800 m 2 site, which it says will be the world's first for industrial-scale lead-212 radiopharmaceuticals. "The development of radiopharmaceuticals has long been hampered by the difficulty of manufacturing and distributing on an industrial scale, " Orano says in a press statement, adding that the new facility is a major step toward filling that gap. Another biotech firm, ITM Isotope Technologies Munich in Germany, raised 201 million in June to develop its radiopharmaceutical pathway and prepare to produce its lead candidate, ITM-11, which is in Phase 3 clinical trials for gastroenteropancreatic neuroendocrine tumors. The Singapore-owned investment firm Temasek led the funding round with participation from BlackRock Alternatives,
Aayushi Pratap (Mon,) studied this question.